ChromaDex to begin the first human trials
date:Apr 22, 2013
wed PURENERGY had a 6-8 times longer half-life compared to caffeine alone. The results of the animal study are said to suggest that PURENERGY may provide longer sustained energy and alertness with reduced amounts of caffeine and without the crash typically experienced when ingesting caffeinated energy products.

The clinical trial is designed to determine the safety, relative bioavailability and pharmacokinetics of PURENERGYs compared to pterostilbene and caffeine alone. The start of this trial
3/4 next page prev page home page last page
go back |  refresh |  WAP home |  Web page version  | login
07/01 00:45